{"id":"NCT03158285","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-12","primaryCompletion":"2019-02-25","completion":"2020-11-10","firstPosted":"2017-05-18","resultsPosted":"2020-11-05","lastUpdate":"2022-12-22"},"enrollment":741,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Psoriatic"],"interventions":[{"type":"DRUG","name":"Guselkumab","otherNames":["CNTO 1959"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Group 1: Guselkumab","type":"EXPERIMENTAL"},{"label":"Group 2: Guselkumab and Placebo","type":"EXPERIMENTAL"},{"label":"Group 3: Placebo Followed by Guselkumab","type":"EXPERIMENTAL"}],"summary":"The primary purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"Placebo to Guselkumab 100 mg q4w","deltaMin":32.9,"sd":null},{"arm":"Guselkumab 100 mg q8w","deltaMin":64.1,"sd":null},{"arm":"Guselkumab 100 mg q4w","deltaMin":63.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"},{"comp":"OG000 vs OG002","p":"< 0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":138,"countries":["United States","Bulgaria","Czechia","Estonia","Latvia","Lithuania","Malaysia","Poland","Russia","Spain","Taiwan","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["40690163","39493888","39320583","39261446","38844682","38765190","38488975","38472528","38386178","38310261","37906417","37819505","36828643","36642439","35947349","35947348","35766811","35352313","35296534","34261541","34011674","33934076","33822898","33043600","32178766"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":246},"commonTop":["Alanine Aminotransferase Increased","Upper Respiratory Tract Infection","Aspartate Aminotransferase Increased","Nasopharyngitis","Bronchitis"]}}